GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

AKBA · Dec 31, 2023

Akebia Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001628280-24-011270General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

17.82% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-12.02% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

8.06% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

61.90% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-23.77% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

32.41% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.79% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History12 statesHistory building

Sep 30, 20230/8 normalizedLevel 3 Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20250/9 normalizedLevel 3 Sep 30, 20257/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20268/9 normalizedLevel 3 Jun 30, 20268/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 101.35%
Current: 17.82%
Delta: -83.53%

Cash Generation Increased

Previous: -17.05%
Current: -12.02%
Delta: 5.03%

Inventory Pressure Decreased

Previous: 43.86%
Current: 8.06%
Delta: -35.80%

Margin Increased

Previous: 57.17%
Current: 61.90%
Delta: 4.73%

Profitability Increased

Previous: -31.00%
Current: -23.77%
Delta: 7.24%

R And D Intensity Increased

Previous: 31.70%
Current: 32.41%
Delta: 0.71%

Sbc Intensity Increased

Previous: 4.34%
Current: 4.79%
Delta: 0.45%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · AKBA Fundamental State →Transitioned To · AKBA Fundamental State →Transitioned To · AKBA BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · AKBA CASH_GENERATION_INCREASED →Transitioned To · AKBA INVENTORY_PRESSURE_DECREASED →Transitioned To · AKBA MARGIN_INCREASED →Transitioned To · AKBA PROFITABILITY_INCREASED →Transitioned To · AKBA R_AND_D_INTENSITY_INCREASED →Transitioned To · AKBA SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.